Compare Mesoblast Limited (MESO) vs Nu Holdings Ltd (NU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Nu Holdings Ltd — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.16B), while Nu Holdings Ltd trades at $13.65 (market cap $66.85B). The key difference: Nu Holdings Ltd is far larger — about 30.9× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Nu Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| MESO | NU | |
|---|---|---|
Market Cap | $2.16B | $66.85B |
Sector | Technology | Financials |
52-Week High | $20.96 | $18.76 |
52-Week Low | $12.88 | $11.60 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Nu Holdings (NU) trades at $13.84, down 1.98% with a bearish technical outlook. The company shows strong fundamental growth with revenue increasing from $3.0B in 2022 to $10.6B in 2025 and net income turning positive to $2.9B. Recent earnings show mixed results with two misses but a beat in Q3 2025. Analyst consensus remains bullish with a $14.98 price target despite recent price weakness.
Nu presents a compelling growth story with expanding profitability and market position in Latin American banking. Key risks include unsecured credit exposure and regional economic volatility. The current valuation at 21.35 P/E offers potential upside if the company maintains its growth trajectory and executes on expansion plans in Brazil and Mexico.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →
